Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Scand J Gastroenterol. 2019 Jan;54(1):95-100. doi: 10.1080/00365521.2018.1561937. Epub 2019 Jan 20.

Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma.

Author information

1
a Department of Gastroenterology , The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University , Wenzhou , China.
2
b Department of Surgery , Clinical Sciences Lund Lund University and Skåne University Hospital , Lund , Sweden.
3
c Department of Pathology , Skåne University Hospital , Lund , Sweden.

Abstract

BACKGROUND:

Galectins are a group of carbohydrate-binding proteins that are involved in neoplastic development and progression. In a previous mass spectrometry-based study, we identified galectin 4 as a down-regulated protein in short-term survivors of pancreatic cancer. This study was performed to validate the prognostic value of galectin 4 in a larger cohort of pancreatic cancer patients undergoing surgical resection.

METHODS:

Galectin 4 expression was evaluated by tissue microarrays and immunohistochemistry in 140 patients with surgically resected pancreatic cancer. Kaplan-Meier and Cox proportional hazards modeling were used to explore the association between galectin 4 and survival.

RESULTS:

Galectin 4 staining expression was positive in 111 cases (79.3%). The expression of galectin 4 was significantly associated with tumor size (p = .008) and differentiation (p = .001). Galectin 4 expression was significantly correlated with disease recurrence within 1 year of surgery (adjusted HR 0.485, p = .027). There was also a significant association between galectin 4 and overall survival at 1 year (adjusted HR 0.482, p = .047) and at 3 years (adjusted HR 0.550, p = .025).

CONCLUSION:

Galectin 4 expression is a novel biomarker for early recurrence and mortality after surgical resection for pancreatic cancer.

KEYWORDS:

LGALS4; Pancreatic cancer; early recurrence; galectin 4; survival

PMID:
30663442
DOI:
10.1080/00365521.2018.1561937
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center